Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy ...

This licence allows individuals, commercial organisations and non-commercial organisations to reuse NICE content free of charge in their publications, products and systems. It applies to requests to ...

A list of downloadable documents created during development.

NICE Pathways offer an easy-to-use, intuitive way of accessing our clinical, public health and social care information. They include up to date NICE guidance, quality standards and related information ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

NHS England proposes that patients likely to achieve the greatest clinical benefit from weight loss are prioritised to receive the medication in a variety of new services that will be tested before an ...

A list of downloadable documents created during development.

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...